David Pierre
About David Pierre
David Pierre is Chief Executive Officer of Machinify, a healthcare intelligence and payment integrity platform backed by New Mountain Capital, and joined Machinify in September 2024 after serving as COO of Signify Health where he led over $1B in revenue and helped drive the IPO (2021) and sale to CVS Health (2023) . He was appointed a director of Performant Healthcare’s surviving corporation at the close of Machinify’s acquisition on October 21, 2025 . He holds a BA in Psychology (SMU) and an MBA (Chicago Booth) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Signify Health | Chief Operating Officer; Business leader for Home & Community | 2016–2023 | Led >$1B revenue; scaled to IPO (2021) and sale to CVS Health (2023) |
| Cerner Corporation | Vice President/GM; led Hospital Ops and Pediatrics business units | ~9 years (prior to 2016) | Operated multiple BU P&Ls and growth initiatives |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Machinify | Chief Executive Officer | Sep 2024–present | Leads NMCap-backed platform; rebranded and expanded payment integrity footprint |
| Sonrava Health | Director | Not disclosed | Board role per NMCap team profile |
| Benevis | Director | Not disclosed | Board role per NMCap team profile |
Board Governance
- Appointment and status: Upon closing of the merger on Oct 21, 2025, David Pierre (with TG Ganeshan) became a director of the Surviving Corporation; prior Nasdaq-listed PHLT directors resigned at the Effective Time .
- Independence: PHLT’s pre-merger board identified independent directors (Hansen, LaCamp, Yanagi, Fluegel, Agrawal), which did not include Pierre . Post-merger, Pierre is CEO of Machinify (Parent), indicating affiliation with the controlling owner rather than independence .
- Committees/chair roles: Post-merger committee assignments were not disclosed in the 8-K; the Surviving Corporation amended and restated its charter and bylaws, resetting governance framework .
- Attendance/engagement: Not disclosed for Pierre; pre-merger directors recorded 100% attendance in 2024 meetings and committees (context for prior governance baseline) .
Other Directorships & Interlocks
| Company | Public/Private | Role | Potential Interlock/Exposure |
|---|---|---|---|
| Machinify | Private | CEO | Direct control link to PHLT Surviving Corporation post-acquisition; acquirer/parent role |
| Sonrava Health | Private | Director | Provider services; potential ecosystem ties in healthcare revenue cycles |
| Benevis | Private | Director | Pediatric Medicaid dental; governance exposure to payer/provider payments |
Expertise & Qualifications
- Healthcare technology/operator: Nearly 20 years scaling health-tech platforms across payment integrity and clinical ops; Cerner BU leadership; Signify Health operational scaling .
- Payment integrity/AI platform leadership: Steers Machinify’s unified AI+expertise model across payers and government programs .
- Credentials: Fellow of the American College of Healthcare Executives; BA (SMU), MBA (Chicago Booth) .
Governance Assessment
- Independence and conflicts: Pierre is the CEO of Machinify (Parent) and became director of the Surviving Corporation at closing—this alignment with the controlling owner implies a non-independent status and potential conflicts when evaluating related-party transactions, strategy, and executive compensation .
- Corporate opportunities waiver: The post-merger charter renounces corporate opportunities for non-employee directors/officers/stockholders, potentially prioritizing Parent/affiliate opportunities over the Surviving Corporation—this is a governance risk indicator for minority stakeholders if any .
- Indemnification/exculpation: The amended charter provides broad director exculpation and indemnification with expense advancement, increasing protection for directors but reducing recourse, a common PE-owned structure; investors should consider potential impacts on accountability .
- Related-party transactions (context): Pre-merger, PHLT disclosed no related-party transactions in 2024 under its policy; post-merger, Parent control and Pierre’s dual role elevate the need for robust audit committee oversight on any intercompany dealings (not disclosed to date) .
- Control and listing changes: Delisting and deregistration followed the change in control; shareholder rights transitioned to private-company frameworks under new bylaws—key governance shift to closely held model .
RED FLAGS
- Non-independence due to CEO role at Parent/acquirer while serving as director of Surviving Corporation .
- Corporate opportunities renunciation that can structurally disadvantage the Surviving Corporation when Parent/affiliate opportunities arise .
- Broad indemnification and exculpation provisions that may weaken accountability in conflict scenarios .
Notes on Compensation and Ownership
- Director compensation and ownership: No disclosure for Pierre’s Surviving Corporation director compensation or equity ownership post-merger in available filings; PHLT’s pre-merger independent director pay structure (cash retainer plus RSUs) does not apply, as Pierre joined at closing and the public board was replaced .
- Change-in-control treatment: Equity award treatment at closing for company awards is described, but relates to company option/RSU holders; no Pierre-specific compensation disclosure is present .
Transaction Context
- Acquisition close and role: Machinify completed the acquisition for approximately $670M on Oct 21, 2025; Pierre emphasized strategic fit expanding government program reach and payment accuracy .
- Merger communications: DEFM14A/8-K notices identify Pierre as a Parent/Merger Sub contact, underscoring his leadership in the transaction .